Humana (NYSE:HUM) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen cut shares of Humana (NYSE:HUM – Free Report) from a buy rating to a hold rating in a research note published on Saturday.

HUM has been the subject of a number of other research reports. Mizuho raised their price objective on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Oppenheimer upped their target price on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, May 1st. Guggenheim began coverage on shares of Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price target on the stock. Robert W. Baird increased their price objective on shares of Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $280.76.

Read Our Latest Stock Report on Humana

Humana Price Performance

NYSE:HUM opened at $227.13 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The stock has a market cap of $27.41 billion, a P/E ratio of 16.06, a PEG ratio of 1.74 and a beta of 0.44. The company has a fifty day moving average price of $237.18 and a 200 day moving average price of $258.14. Humana has a one year low of $212.45 and a one year high of $406.46.

Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. During the same quarter in the prior year, the business earned $7.23 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. Analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.56%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio (DPR) is currently 25.04%.

Hedge Funds Weigh In On Humana

Several hedge funds have recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC acquired a new position in Humana during the fourth quarter valued at approximately $202,000. Proficio Capital Partners LLC acquired a new position in shares of Humana in the 4th quarter valued at $14,097,000. Raymond James Financial Inc. bought a new stake in shares of Humana in the 4th quarter valued at $26,720,000. Independent Advisor Alliance raised its stake in Humana by 9.2% during the 4th quarter. Independent Advisor Alliance now owns 2,338 shares of the insurance provider’s stock worth $593,000 after buying an additional 197 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in Humana by 4.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,103 shares of the insurance provider’s stock worth $533,000 after acquiring an additional 81 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading